Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss

Bio-Rad Laboratories Inc. (BIO) reported Q1 2026 revenue of $592.1 million, up 1.1% year over year. The quarter included a gross profit of $309.4 million and an operating profit of $34.1 million, a strong increase versus the prior year.

Revenue: $592.1 million (+1.1% YoY)

Gross profit: $309.4 million (+1.1% YoY)

Operating profit: $34.1 million (+43.9% YoY)

Net loss attributable to common shareholders: $527.1 million (loss; -923.6% YoY)

Diluted EPS: -19.55 (vs. estimate 2.00)

Revenue came in slightly below the consensus estimate of $594.8 million, while diluted EPS of -19.55 missed the estimated 2.00.

Cash from operating activities: $216.2 million (+66.4% YoY)

Purchases of property, plant and equipment: $30.0 million (down 12.8% YoY)

Cash and cash equivalents: $507.2 million (down 2.7% YoY)

Total liabilities: $2.94 billion (+3.2% YoY)

The quarter shows improving operating performance and stronger operating cash flow, but a sizable GAAP net loss drove earnings per share deeply negative for Q1 2026.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

EARLY ACCESS

Receive BIO Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

Bio-Rad Laboratories Inc. Hedge Fund Activity

We have seen 161 institutional investors add shares of Bio-Rad Laboratories Inc. stock to their portfolio, and 190 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,193,607 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $361,650,984
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 390,593 shares (+4534.4%) to their portfolio in Q4 2025, for an estimated $118,345,773
VERITAS ASSET MANAGEMENT LLP removed 300,704 shares (-35.6%) from their portfolio in Q4 2025, for an estimated $91,110,304
BOSTON PARTNERS added 247,612 shares (+inf%) to their portfolio in Q4 2025, for an estimated $75,023,959
ROYAL BANK OF CANADA removed 161,380 shares (-91.6%) from their portfolio in Q4 2025, for an estimated $48,896,526
ASSENAGON ASSET MANAGEMENT S.A. added 145,623 shares (+6586.3%) to their portfolio in Q1 2026, for an estimated $40,592,411
FREESTONE GROVE PARTNERS LP added 110,524 shares (+inf%) to their portfolio in Q4 2025, for an estimated $33,487,666

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Bio-Rad Laboratories Inc. Government Contracts

We have seen $4,119,012 of award payments to $BIO over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

LYPHOCHEK WHOLE BLOOD METALS CONTROL - QUALITY CONTROL REAGENTS: $405,324
SEROLOGICAL AUTOMATED ANALYZERS FOR HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS TESTING FOR MILITARY...: $349,963
CONSUMABLES AND REAGENT PRODUCTS FOR SEROLOGICAL AUTOMATED ANALYZER SYSTEMS.: $244,260
IMMUNOLOGY: $235,226
BIOPLEX REAGENTS AND CONSUMABLES: $200,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.